Current and future pharmaceutical therapy for rheumatoid arthritis

Current Pharmaceutical Design

Volumn 11, Issue 5, 2005, Pages 671-684

  Ruderman, Eric M ^a,b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b NONE   (United States)

Author keywords

Adalimumab; Biologic response modifier; DMARD; Etanercept; Infliximab; Methotrexate; Rheumatoid arthritis; TNF antagonist

Indexed keywords

ABATACEPT; ADALIMUMAB; ANTIINFLAMMATORY AGENT; ANTIRHEUMATIC AGENT; AZATHIOPRINE; CHLOROQUINE; COLESTYRAMINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; ETANERCEPT; HYDROXYCHLOROQUINE; INFLIXIMAB; INTERLEUKIN 1; INTERLEUKIN 6 ANTIBODY; LEFLUNOMIDE; METHOTREXATE; PENICILLAMINE; PLACEBO; PREDNISOLONE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNCLASSIFIED DRUG;

CANCER RISK; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DEMYELINATING DISEASE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENTIATION; DRUG RESPONSE; HUMAN; INJECTION SITE REACTION; LIVER TOXICITY; LYMPHOMA; MONOTHERAPY; NEPHROTOXICITY; PRIORITY JOURNAL; PROTEINURIA; REVIEW; RHEUMATOID ARTHRITIS; SIDE EFFECT; SKIN MANIFESTATION; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; TERATOGENICITY; TUBERCULOSIS;

ARTHRITIS, RHEUMATOID; DOUBLE-BLIND METHOD; DRUG THERAPY; FOLLOW-UP STUDIES; HUMANS; MULTICENTER STUDIES; PHARMACEUTICAL PREPARATIONS; RANDOMIZED CONTROLLED TRIALS; TECHNOLOGY, PHARMACEUTICAL; TIME FACTORS;

EID: 14044263544     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/1381612053381954     Document Type: Review

References (106)

1. Paulus HE, Egger MJ, Ward JR, Williams HJ. Analysis of improvement in individual rheumatoid arthritis patients treated with disease-modifying antirheumatic drugs, based on the findings in patients treated with placebo. The Cooperative Systematic Studies of Rheumatic Diseases Group. Arthritis Rheum 1990; 33(4): 477-84.
2. Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995; 38(6): 727-35.
3. Wolfe F, Sharp JT. Radiographic outcome of recent-onset rheumatoid arthritis: a 19-year study of radiographic progression. Arthritis Rheum 1998; 41(9): 1571-82.
4. van der Heide A, Remme CA, Hofman DM, Jacobs JW, Bijlsma JW. Prediction of progression of radiologic damage in newly diagnosed rheumatoid arthritis. Arthritis Rheum 1995; 38(10): 1466-74.
5. Kuper HH, van Leeuwen MA, van Riel PL, Prevoo ML, Houtman PM, Lolkema WF, et al. Radiographic damage in large joints in early rheumatoid arthritis: relationship with radiographic damage in hands and feet, disease activity, and physical disability. Br J Rheumatol 1997; 36(8): 855-60.
6. Fuchs H, Kaye J, Callahan L, Nance E, Pincus T. Evidence of significant radiographic damage in rheumatoid arthritis within the first 2 years of disease. J Rheumatol 1989; 16: 585-91.
7. McQueen FM, Stewart N, Crabbe J, Robinson E, Yeoman S, Tan PL, et al. Magnetic resonance imaging of the wrist in early rheumatoid arthritis reveals a high prevalence of erosions at four months after symptom onset. Ann Rheum Dis 1998; 57(6): 350-6.
8. van der Heijde DM, van Leeuwen M, van Riel P, van de Putte L. Radiographic progression on radiographs of hands and feet during the first 3 years of rheumatoid arthritis measured according to Sharp's method (van der Heijde modification). J Rheumatol 1995; 22: 1792-96.
9. Larsen A. How to apply Larsen score in evaluating radiographs of rheumatoid arthritis in long-term studies. J Rheumatol 1995; 22(10): 1974-5.
10. Sharp JT, Wolfe F, Mitchell DM, Bloch DA. The progression of erosion and joint space narrowing scores in rheumatoid arthritis during the first twenty-five years of disease. Arthritis Rheum 1991; 34(6): 660-8.
11. Wolfe F, Hawley D. Work disability in Rheumatoid Arthritis. Journal of Rheumatology 1998; 25: 2108-2117.
12. Kirwin J. Links between radiological change, disability, and pathology in rheumatoid arthritis. J Rheumatol 2001; 28: 881-86.
13. Yelin E, Wanke LA. An assessment of the annual and long-term direct costs of rheumatoid arthritis: the impact of poor function and functional decline. Arthritis Rheum 1999; 42(6): 1209-18.
14. Fries JF, Spitz PW, Young DY. The dimensions of health outcomes: the health assessment questionnaire, disability and pain scales. J Rheumatol 1982; 9(5): 789-93.
15. Wolfe F, Kleinheksel SM, Cathey MA, Hawley DJ, Spitz PW, Fries JF. The clinical value of the Stanford Health Assessment Questionnaire Functional Disability Index in patients with rheumatoid arthritis. J Rheumatol 1988; 15(10): 1480-8.
16. Williams HJ, Willkens RF, Samuelson CO Jr, Alarcon GS, Guttadauria M, Yarboro C, et al. Comparison of low-dose oral pulse methotrexate and placebo in the treatment of rheumatoid arthritis. A controlled clinical trial. Arthritis Rheum 1985; 28(7): 721-30.
17. Weinblatt ME, Coblyn JS, Fox DA, Fraser PA, Holdsworth DE, Glass DN, et al. Efficacy of low-dose methotrexate in rheumatoid arthritis. N Engl J Med 1985; 312(13): 818-22.
18. Kremer JM, Genovese MC, Cannon GW, Caldwell JR, Cush JJ, Furst DE, et al. Concomitant leflunomide therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 2002; 137(9): 726-33.
19. Tugwell P, Pincus T, Yocum D, Stein M, Gluck O, Kraag G, et al. Combination therapy with cyclosporine and methotrexate in severe rheumatoid arthritis. The Methotrexate-Cyclosporine Combination Study Group. N Engl J Med 1995; 333(3): 137-41.
20. Boers M, Verhoeven AC, Markusse HM, van de Laar MA, Westhovens R, van Denderen JC, et al. Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet 1997; 350(9074): 309-18.
21. O'Dell J, Haire C, Erikson N. Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications. N Engl J Med 1996; 334: 287-91.
22. O'Dell J, Leff R, Paulsen G. Treatment of rheumatoid arthritis with methotrexate and hydroxychloroquine, methotrexate and sulfasalazine, or a combination of the three medications: results of a two-year, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002; 46: 1164-70.
23. Pincus T, O'Dell JR, Kremer JM. Combination therapy with multiple disease-modifying antirheumatic drugs in rheumatoid arthritis: a preventive strategy. Ann Intern Med 1999; 131(10): 768-74.
24. Williams HJ, Ward JR, Reading JC, Egger MJ, Grandone JT, Samuelson CO, et al. Low-dose D-penicillamine therapy in rheumatoid arthritis. A controlled, double-blind clinical trial. Arthritis Rheum 1983; 26(5): 581-92.
25. Jessop JD, O'Sullivan MM, Lewis PA, Williams LA, Camilleri JP, Plant MJ, et al. A long-term five-year randomized controlled trial of hydroxychloroquine, sodium aurothiomalate, auranofin and penicillamine in the treatment of patients with rheumatoid arthritis. Br J Rheumatol 1998; 37(9): 992-1002.
26. van Rijthoven AW, Dijkmans BA, The HS, Meijers KA, Montnor-Beckers ZL, Moolenburgh JD, et al. Comparison of cyclosporine and D-penicillamine for rheumatoid arthritis: a randomized, double blind, multicenter study. J Rheumatol 1991; 18(6): 815-20.
27. Gibson T, Emery P, Armstrong RD, Crisp AJ, Panayi GS. Combined D-penicillamine and chloroquine treatment of rheumatoid arthritis - a comparative study. Br J Rheumatol 1987; 26(4): 279-84.
28. Landewe RB, Goei The HS, van Rijthoven AW, Breedveld FC, Dijkmans BA. A randomized, double-blind, 24-week controlled study of low-dose cyclosporine versus chloroquine for early rheumatoid arthritis. Arthritis Rheum 1994; 37(5): 637-43.
29. Emery P, Breedveld FC, Lemmel EM, Kaltwasser JP, Dawes PT, Gomor B, et al. A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis. Rheumatology (Oxford) 2000; 39(6): 655-65.
30. Smolen JS, Kalden JR, Scott DL, Rozman B, Kvien TK, Larsen A, et al. Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. European Leflunomide Study Group. Lancet 1999; 353(9149): 259-66.
31. Strand V, Cohen S, Schiff M, Weaver A, Fleischmann R, Cannon G, et al. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group. Arch Intern Med 1999; 159(21): 2542-50.
32. Weinblatt ME, Kaplan H, Germain BF, Merriman RC, Solomon SD, Wall B, et al. Low-dose methotrexate compared with auranofin in adult rheumatoid arthritis. A thirty-six-week, double-blind trial. Arthritis Rheum 1990; 33(3): 330-8.
33. Woodland J, Chaput de Saintonge DM, Evans SJ, Sharman VL, Currey HL. Azathioprine in rheumatoid arthritis: double-blind study of full versus half doses versus placebo. Ann Rheum Dis 1981; 40(4): 355-9.
34. Halberg P, Bentzon MW, Crohn O, Gad I, Halskov O, Heyn J, et al. Double-blind trial of levamisole, penicillamine and azathioprine in rheumatoid arthritis. Clinical, biochemical, radiological and scintigraphic studies. Dan Med Bull 1984; 31(5): 403-9.
35. Jeurissen ME, Boerbooms AM, van de Putte LB, Doesburg WH, Lemmens AM. Influence of methotrexate and azathioprine on radiologic progression in rheumatoid arthritis. A randomized, double-blind study. Ann Intern Med 1991; 114(12): 999-1004.
36. Erkan D, Yazici Y, Harrison M, Paget SA. Rheumatologists' optimal choice of first-line rheumatoid arthritis (RA) therapy in 2002. In: European League Against Rheumatism; 2003; June 18-21; Lisbon, Portugal; 2003; p. AB0641.
37. Sharp JT, Strand V, Leung H, Hurley F, Loew-Friedrich I. Treatment with leflunomide slows radiographic progression of rheumatoid arthritis: results from three randomized controlled trials of leflunomide in patients with active rheumatoid arthritis. Leflunomide Rheumatoid Arthritis Investigators Group. Arthritis Rheum 2000; 43(3): 495-505.
38. Weinblatt ME, Dixon JA, Falchuk KR. Serious liver disease in a patient receiving methotrexate and leflunomide. Arthritis Rheum 2000; 43(11): 2609-11.
39. Goldkind L, Simon LS. Safety and efficacy update on leflunomide (Arava). Atlanta, GA: ACR Hotline; May 2003.
40. Brent RL. Teratogen update: reproductive risks of leflunomide (Arava); a pyrimidine synthesis inhibitor: counseling women taking leflunomide before or during pregnancy and men taking leflunomide who are contemplating fathering a child. Teratology 2001; 63(2): 106-12.
41. Rozman B. Clinical pharmacokinetics of leflunomide. Clin Pharmacokinet 2002; 41(6): 421-30.
42. Ferraccioli GF, Gremese E, Tomietto P, Favret G, Damato R, Di Poi E. Analysis of improvements, full responses, remission and toxicity in rheumatoid patients treated with step-up combination therapy (methotrexate, cyclosporin A, sulphasalazine) or monotherapy for three years. Rheumatology (Oxford) 2002; 41(8): 892-8.
43. Baraldo M, Ferraccioli G, Pea F, Gremese E, Furlanut M. Cyclosporine A pharmacokinetics in rheumatoid arthritis patients after 6 months of methotrexate therapy. Pharmacol Res 1999; 40(6): 483-6.
44. Marchesoni A, Battafarano N, Arreghini M, Pellerito R, Cagnoli M, Prudente P, et al. Step-down approach using either cyclosporin A or methotrexate as maintenance therapy in early rheumatoid arthritis. Arthritis Rheum 2002; 47(1): 59-66.
45. Landewe RB, Boers M, Verhoeven AC, Westhovens R, van de Laar MA, Markusse HM, et al. COBRA combination therapy in patients with early rheumatoid arthritis: long-term structural benefits of a brief intervention. Arthritis Rheum 2002; 46(2): 347-56.
46. Maillefert JF, Combe B, Goupille P, Cantagrel A, Dougados M, Long term structural effects of combination therapy in patients with early rheumatoid arthritis: five year follow up of a prospective double blind controlled study. Ann Rheum Dis 2003; 62(8): 764-6.
47. Mottonen T, Hannonen P, Leirisalo-Repo M, Nissila M, Kautiainen H, Korpela M, et al. Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. FIN-RACo trial group. Lancet 1999; 353(9164): 1568-73.
48. Feldmann M, Brennan FM, Maini RN. Rheumatoid arthritis. Cell 1996; 85(3): 307-10.
49. Choy EH, Panayi GS. Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 2001; 344(12): 907-16.
50. Saxne T, Palladino MA Jr, Heinegard D, Talal N, Wollheim FA. Detection of tumor necrosis factor alpha but not tumor necrosis factor beta in rheumatoid arthritis synovial fluid and serum. Arthritis Rheum 1988; 31(8): 1041-5.
51. Eastgate JA, Symons JA, Wood NC, Grinlinton FM, di Giovine FS, Duff GW. Correlation of plasma interleukin 1 levels with disease activity in rheumatoid arthritis. Lancet 1988; 2(8613): 706-9.
52. Moreland LW, Alten R, Van den Bosch F, Appelboom T, Leon M, Emery P, et al. Costimulatory blockade in patients with rheumatoid arthritis: a pilot, dose-finding, double-blind, placebo-controlled clinical trial evaluating CTLA-4Ig and LEA29Y eighty-five days after the first infusion. Arthritis Rheum 2002; 46(6): 1470-9.
53. Kremer JM, Westhovens R, Leon M, Di Giorgio E, Alten R, Steinfeld S, et al. Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N Engl J Med 2003; 349(20): 1907-15.
54. Choy EH, Isenberg DA, Garrood T, Farrow S, Ioannou Y, Bird H, et al. Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: a randomized, double-blind, placebo-controlled, dose-escalation trial. Arthritis Rheum 2002; 46(12): 3143-50.
55. Elliott MJ, Maini RN, Feldmann M, Kalden JR, Antoni C, Smolen JS, et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet 1994; 344(8930): 1105-10.
56. Maini R, St Clair EW, Breedveld F, Furst D, Kalden J, Weisman M, et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 1999; 354(9194): 1932-9.
57. Maini RN, Breedveld FC, Kalden JR, Smolen JS, Davis D, Macfarlane JD, et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998; 41(9): 1552-63.
58. Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 2000; 343(22): 1594-602.
59. Boers M. Demonstration of response in rheumatoid arthritis patients who are nonresponders according to the American College of Rheumatology 20% criteria: the paradox of beneficial treatment effects in nonresponders in the ATTRACT trial. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy. Arthritis Rheum 2001; 44(11): 2703-4.
60. Lipsky PE, Felson DT, Maini RN. Blocking tumor necrosis factor inhibits radiographic damage even in patients who show minimal or no clinical improvement: comment on the concise communication by Boers. Arthritis Rheum 2002; 46(10): 2817-8; author reply 2718-21.
61. Smolen J, Maini R, Keystone E, Bathon JM, Emery P, Kalden J, et al. Treatment of early rheumatoid arthritis with infliximab plus methotrexate or methotrexate alone: Preliminary results of the ASPIRE trial. In: European League Against Rheumatism; 2003 June 18-21; Lisbon, Portugal; 2003; p. OP0001.
62. de Vries-Bouwstra JK, Goekoop-Ruiterman Y, Breedveld F, Han KH, Kerstens P, Ronday HK, et al. Clinical and Radiological Outcomes after One-Year Follow-Up of the BeSt Study, a Randomized Trial Comparing Four Different Treatment Strategies in Early Rheumatoid Arthritis (RA). In: American College of Rheumatology; 2003; Orlando, FL; 2003; p. LB18.
63. Machold KP, Smolen JS. Adalimumab - a new TNF-alpha antibody for treatment of inflammatory joint disease. Expert Opin Biol Ther 2003; 3(2): 351-60.
64. van de Putte LB, Rau R, Breedveld FC, Kalden JR, Malaise MG, van Riel PL, et al. Efficacy and safety of the fully human anti-tumour necrosis factor alpha monoclonal antibody adalimumab (D2E7) in DMARD refractory patients with rheumatoid arthritis: a 12 week, phase II study. Ann Rheum Dis 2003; 62(12): 1168-77.
65. Weinblatt ME, Keystone EC, Furst DE, Moreland LW, Weisman MH, Birbara CA, et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 2003; 48(1): 35-45.
66. Rau R. Adalimumab (a fully human anti-tumour necrosis factor alpha monoclonal antibody) in the treatment of active rheumatoid arthritis: the initial results of five trials. Ann Rheum Dis 2002; 61 Suppl 2: ii70-3.
67. Moreland LW, Schiff MH, Baumgartner SW, Tindall EA, Fleischmann RM, Bulpitt KJ, et al. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med 1999; 130(6): 478-86.
68. Weinblatt ME, Kremer JM, Bankhurst AD, Bulpitt KJ, Fleischmann RM, Fox RI, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999; 340(4): 253-9.
69. Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, Keystone EC, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000; 343(22): 1586-93.
70. Genovese MC, Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, et al. Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes. Arthritis Rheum 2002; 46(6): 1443-50.
71. Klareskog L, van der Heijde D, de Jager JP, Gough A, Kalden J, Malaise M, et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 2004; 363(9410): 675-81.
72. Moreland L, Baumgartner SW, Schiff M, Tindall EA, Fleischmann R, Weaver A, et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med 1997; 337(3): 141-7.
73. Moreland LW, Cohen SB, Baumgartner SW, Tindall EA, Bulpitt K, Martin R, et al. Long-term safety and efficacy of etanercept in patients with rheumatoid arthritis. J Rheumatol 2001; 28(6): 1238-44.
74. Catrina AI, Lampa J, Ernestam S, af Klint E, Bratt J, Klareskog L, et al. Anti-tumour necrosis factor (TNF)-alpha therapy (etanercept) down-regulates serum matrix metalloproteinase (MMP)-3 and MMP-1 in rheumatoid arthritis. Rheumatology (Oxford) 2002; 41(5): 484-9.
75. Lugering A, Schmidt M, Lugering N, Pauels HG, Domschke W, Kucharzik T. Infliximab induces apoptosis in monocytes from patients with chronic active Crohn's disease by using a caspase-dependent pathway. Gastroenterology 2001; 121(5): 1145-57.
76. Zou J, Rudwaleit M, Brandt J, Thiel A, Braun J, Sieper J. Down-regulation of the nonspecific and antigen-specific T cell cytokine response in ankylosing spondylitis during treatment with infliximab. Arthritis Rheum 2003; 48(3): 780-90.
77. Ulfgren AK, Andersson U, Engstrom M, Klareskog L, Maini RN, Taylor PC. Systemic anti-tumor necrosis factor alpha therapy in rheumatoid arthritis down-regulates synovial tumor necrosis factor alpha synthesis. Arthritis Rheum 2000; 43(11): 2391-6.
78. Zou J, Rudwaleit M, Brandt J, Thiel A, Braun J, Sieper J. Up regulation of the production of tumour necrosis factor alpha and interferon gamma by T cells in ankylosing spondylitis during treatment with etanercept. Ann Rheum Dis 2003; 62(6): 561-4.
79. Van den Brande JM, Braat H, van den Brink GR, Versteeg HH, Bauer CA, Hoedemaeker I, et al. Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease. Gastroenterology 2003; 124(7): 1774-85.
80. van Dullemen HM, van Deventer SJ, Hommes DW, Bijl HA, Jansen J, Tytgat GN, et al. Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology 1995; 109(1): 129-35.
81. Sandborn WJ, Hanauer SB, Katz S, Safdi M, Wolf DG, Baerg RD, et al. Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology 2001; 121(5): 1088-94.
82. Ellerin T, Rubin RH, Weinblatt ME. Infections and anti-tumor necrosis factor alpha therapy. Arthritis Rheum 2003; 48(11): 3013-22.
83. Phillips K, Husni ME, Karlson EW, Coblyn JS. Experience with etanercept in an academic medical center: are infection rates increased? Arthritis Rheum 2002; 47(1): 17-21.
84. Gardam MA, Keystone EC, Menzies R, Manners S, Skamene E, Long R, et al. Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management. Lancet Infect Dis 2003; 3(3): 148-55.
85. Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001; 345(15): 1098-104.
86. Gomez-Reino JJ, Carmona L, Valverde VR, Mola EM, Montero MD. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum 2003; 48(8): 2122-7.
87. Slifman NR, Gershon SK, Lee JH, Edwards ET, Braun MM. Listeria monocytogenes infection as a complication of treatment with tumor necrosis factor alpha-neutralizing agents. Arthritis Rheum 2003; 48(2): 319-24.
88. Lee JH, Slifman NR, Gershon SK, Edwards ET, Schwieterman WD, Siegel JN, et al. Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor alpha antagonists infliximab and etanercept. Arthritis Rheum 2002; 46(10): 2565-70.
89. Brown SL, Greene MH, Gershon SK, Edwards ET, Braun MM. Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration. Arthritis Rheum 2002; 46(12): 3151-8.
90. Chung ES, Packer M, Lo KH, Fasanmade AA, Willerson JT. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation 2003; 107(25): 3133-40.
91. Kwon HJ, Cote TR, Cuffe MS, Kramer JM, Braun MM. Case reports of heart failure after therapy with a tumor necrosis factor antagonist. Ann Intern Med 2003; 138(10): 807-11.
92. Shakoor N, Michalska M, Harris CA, Block JA. Drug-induced systemic lupus erythematosus associated with etanercept therapy. Lancet 2002; 359(9306): 579-80.
93. De Rycke L, Kruithof E, Van Damme N, Hoffman IE, Van den Bossche N, Van den Bosch F, et al. Antinuclear antibodies following infliximab treatment in patients with rheumatoid arthritis or spondylarthropathy. Arthritis Rheum 2003; 48(4): 1015-23.
94. Arend WP. Interleukin 1 receptor antagonist. A new member of the interleukin 1 family. J Clin Invest 1991; 88(5): 1445-51.
95. Dripps DJ, Verderber E, Ng RK, Thompson RC, Eisenberg SP. Interleukin-1 receptor antagonist binds to the type II interleukin-1 receptor on B cells and neutrophils. J Biol Chem 1991; 266(30): 20311-5.
96. Cohen S, Hurd E, Cush J, Schiff M, Weinblatt ME, Moreland LW, et al. Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002; 46(3): 614-24.
97. Bresnihan B, Alvaro-Gracia JM, Cobby M, Doherty M, Domljan Z, Emery P, et al. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum 1998; 41(12): 2196-204.
98. Jiang Y, Genant HK, Watt I, Cobby M, Bresnihan B, Aitchison R, et al. A multicenter, double-blind, dose-ranging, randomized, placebo-controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis: radiologic progression and correlation of Genant and Larsen scores. Arthritis Rheum 2000; 43(5): 1001-9.
99. Kineret Prescribing Information. 10/21/03. Thousand Oaks, CA: Amgen Inc.; 2003.
100. Bendele AM, Chlipala ES, Scherrer J, Frazier J, Sennello G, Rich WJ, et al. Combination benefit of treatment with the cytokine inhibitors interleukin-1 receptor antagonist and PEGylated soluble tumor necrosis factor receptor type I in animal models of rheumatoid arthritis. Arthritis Rheum 2000; 43(12): 2648-59.
101. Genovese MC, Cohen S, Moreland L, Lium D, Robbins S, Newmark R, et al. Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate. Arthritis Rheum 2004; 50(5): 1412-9.
102. Leandro MJ, Edwards JC, Cambridge G. Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion. Ann Rheum Dis 2002; 61(10): 883-8.
103. Edwards JC, Szczepanski L, Szechinski J, Filipowicz-Susnowska A, Emery P, Close DR, et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004; 350(25): 2572-81.
104. Cohen Y, Polliack A, Nagler A. Treatment of refractory autoimmune diseases with ablative immunotherapy using monoclonal antibodies and/or high dose chemotherapy with hematopoietic stem cell support. Curr Pharm Design 2003; 9(3): 279-88.
105. Jacobsohn DA, Vogelsang GB. Anti-cytokine therapy for the treatment of graft-versus-host disease. Curr Pharm Design 2004; 10(11): 1195-205.
106. Taylor PC. Anti-cytokines and cytokines in the treatment of rheumatoid arthritis. Curr Pharm Design 2003; 9(14): 1095-106.